Commentary - (2025) Volume 14, Issue 1
Received: 02-Mar-2024, Manuscript No. jms-25-164569;
Editor assigned: 04-Mar-2025, Pre QC No. P-164569;
Reviewed: 17-Mar-2025, QC No. Q-164569;
Revised: 24-Mar-2025, Manuscript No. R-164569;
Published:
31-Mar-2025
, DOI: 10.37421/2167-0943.2025.14.391
Citation: Rezaei, Ali. "Exploring the Link between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients."J Metabolic Synd 14 (2025): 391.
Copyright: © 2025 Rezaei A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Psoriasis is widely recognized as a systemic inflammatory disorder rather than merely a skin disease. Immune dysregulation plays a pivotal role in its pathogenesis, with activated T cells and dendritic cells triggering an overproduction of pro-inflammatory cytokines that fuel chronic inflammation. This systemic inflammation not only exacerbates skin manifestations but also extends to various organ systems, predisposing patients to metabolic and cardiovascular complications. Metabolic syndrome is highly prevalent among psoriasis patients, with studies indicating a strong bidirectional relationship between the two conditions. Obesity, a key component of MetS, exacerbates psoriasis severity through increased secretion of inflammatory adipokines such as leptin and resistin, which further stimulate the release of TNF-ÃÂ?± and IL-6. Conversely, psoriasis itself contributes to metabolic dysfunction by promoting insulin resistance and dyslipidemia, creating a vicious cycle of inflammation and metabolic disturbance. Elevated levels of oxidative stress, endothelial dysfunction, and altered lipid metabolism further heighten cardiovascular risk in affected individuals [2].
The impact of psoriasis on quality of life extends beyond its physical symptoms. The chronic and relapsing nature of the disease, combined with its visible lesions, can lead to significant emotional distress and impaired social interactions. Many patients experience feelings of embarrassment, social withdrawal, and diminished self-confidence, which can contribute to psychiatric comorbidities such as depression and anxiety. Furthermore, the presence of metabolic syndrome in psoriasis patients further exacerbates the decline in QoL by imposing additional health burdens, limiting mobility, and increasing the risk of complications such as cardiovascular disease and type 2 diabetes. The inflammatory pathways implicated in psoriasis and MetS have also been linked to neuroinflammation, further reinforcing the association between systemic inflammation and mental health disorders. Studies utilizing QoL assessment tools such as the Dermatology Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI) have demonstrated that psoriasis severity correlates strongly with the degree of QoL impairment, emphasizing the need for holistic disease management [3].
Given the complex interplay between systemic inflammation, metabolic dysfunction, and psychological distress, a multidisciplinary approach is essential for optimizing patient outcomes. Traditional treatments for psoriasis, including systemic agents such as methotrexate, cyclosporine, and biologic therapies targeting TNF-ÃÂ?± and IL-17, have demonstrated efficacy in reducing both skin lesions and systemic inflammation. Recent advances in metabolic-targeted therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, offer promising benefits for psoriasis patients with coexisting MetS by improving metabolic parameters while exerting anti-inflammatory effects. Lifestyle modifications, including weight management, dietary interventions, and regular physical activity, play a crucial role in mitigating both inflammation and metabolic risk factors. Additionally, integrating psychological support into psoriasis management is vital for addressing mental health concerns and enhancing overall well-being. Cognitive-behavioral therapy (CBT), mindfulness-based interventions, and support groups have shown promise in improving coping mechanisms and QoL in psoriasis patients [4].
Despite the growing body of evidence linking psoriasis, MetS, and QoL, several challenges remain in standardizing diagnostic and therapeutic approaches. Variability in MetS definitions, ethnic differences in psoriasis prevalence and metabolic responses, and the influence of genetic and environmental factors contribute to inconsistencies in research findings. Future studies should focus on longitudinal assessments to better understand the long-term impact of systemic inflammation on metabolic health and psychological well-being in psoriasis patients. Additionally, the development of personalized treatment strategies integrating dermatologic, metabolic, and psychiatric care may offer a more comprehensive approach to disease management. This study aims to explore the intricate associations between systemic inflammation, MetS, and QoL in psoriasis patients, highlighting the pathophysiological mechanisms linking these conditions and the implications for clinical management [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Journal of Metabolic Syndrome received 48 citations as per Google Scholar report